@article{210a4c2fba914af785a9f729a831a91e,
title = "Ceramide synthase 2 deletion decreases the infectivity of HIV-1",
abstract = "The lipid composition of human immunodefiency virus 1 (HIV-1) virions is enriched in sphingomyelin, but the roles that sphingomyelin or other sphingolipids might play in the HIV-1 replication pathway have not been elucidated. In human cells, sphingolipid levels are regulated by ceramide synthase (CerS) enzymes that produce ceramides, which can be converted to sphingomyelins, hexosylceramides, and other sphingolipids. In many cell types, CerS2, which catalyzes the synthesis of very long chain ceramides, is the major CerS. We have examined how CerS2 deficiency affects the assembly and infectivity of HIV-1. As expected, we observed that very long chain ceramide, hexosylceramide, and sphingomyelin were reduced in CerS2 knockout cells. CerS2 deficiency did not affect HIV-1 assembly or the incorporation of the HIV-1 envelope (Env) protein into virus particles, but it reduced the infectivites of viruses produced in the CerS2-deficient cells. The reduced viral infection levels were dependent on HIV-1 Env, since HIV-1 particles that were pseudotyped with the Vesicular Stomatitis Virus (VSV) glycoprotein (G) did not exhibit reductions in infectivity. Moreover, cell-cell fusion assays demonstrated that the functional defect of HIV-1 Env in CerS2-deficient cells was independent of other viral proteins. Overall, our results indicate that the altered lipid composition of CerS2-deficient cells specifically inhibit the HIV-1 Env receptor binding and/or fusion processes.",
author = "Eric Barklis and Ayna Alfadhli and Kyle, {Jennifer E} and Bramer, {Lisa M} and Bloodsworth, {Kent J} and Barklis, {Robin Lid} and Leier, {Hans C} and Petty, {R Max} and Zelnik, {Iris D} and Metz, {Thomas O} and Futerman, {Anthony H} and Tafesse, {Fikadu G}",
note = "We are indebted to Dr. Howard Reizman (University of Geneva) for kindly providing the HeLa CerS2 and CerS5 knockout cell populations. We are grateful to CeAnn Romanaggi for assistance with cholesterol experiments, and to Adam Vanarsdall for antibodies used in the initial phases of our studies. We also thank other members of the Barklis and Tafesse labs for their advice, assistance, and support. EB gratefully acknowledges support from the Medial Research Foundation of Oregon (MRF) and from the National Institutes of Health (R01 AI152579). FT was supported by the Collins Medical Trust and NIH grant R21AI133631. Additional support was provided by the National Institutes of Health, National Institute of Environmental Health Sciences grant U2CES030170. The content in this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Lipidomics analyses were performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the U. S. Department of Energy and located at the Pacific Northwest National Laboratory (PNNL) in Richmond, WA. PNNL is a multi-program national laboratory operated by Battelle for the DOE under contract DE-AC05 76RLO 1830.",
year = "2021",
month = jan,
day = "28",
doi = "https://doi.org/10.1016/j.jbc.2021.100340",
language = "الإنجليزيّة",
journal = "The Journal of biological chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
}